Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-21
2010-11-16
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07833966
ABSTRACT:
Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed.
REFERENCES:
patent: 4079038 (1978-03-01), Choi et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4131648 (1978-12-01), Choi et al.
patent: 4138344 (1979-02-01), Choi et al.
patent: 4180646 (1979-12-01), Choi et al.
patent: 4304767 (1981-12-01), Heller et al.
patent: 4946931 (1990-08-01), Heller et al.
patent: 5294604 (1994-03-01), Nussenblatt et al.
patent: 5387589 (1995-02-01), Kulkarni
patent: 5411952 (1995-05-01), Kaswan
patent: 5457182 (1995-10-01), Widerrecht et al.
patent: 5770607 (1998-06-01), Honbo et al.
patent: 5773019 (1998-06-01), Ashton et al.
patent: 5952371 (1999-09-01), Baker et al.
patent: 5968543 (1999-10-01), Heller et al.
patent: 6004565 (1999-12-01), Chiba
patent: 6015815 (2000-01-01), Mollison
patent: 6179817 (2001-01-01), Zhong
patent: 6218423 (2001-04-01), Ross et al.
patent: 6238799 (2001-05-01), Opolski
patent: 6239113 (2001-05-01), Dawson et al.
patent: 6258856 (2001-07-01), Chamberlain et al.
patent: 6306422 (2001-10-01), Batich et al.
patent: 6331313 (2001-12-01), Wong et al.
patent: 6413536 (2002-07-01), Gibson et al.
patent: 6436906 (2002-08-01), Or et al.
patent: 6440942 (2002-08-01), Or et al.
patent: 6462026 (2002-10-01), Or et al.
patent: 6462071 (2002-10-01), Castillejos
patent: 6482799 (2002-11-01), Tuse et al.
patent: 6489335 (2002-12-01), Peyman
patent: 6534693 (2003-03-01), Fischell et al.
patent: 6596296 (2003-07-01), Nelson et al.
patent: 6613355 (2003-09-01), Ng et al.
patent: 6617345 (2003-09-01), Gregory et al.
patent: 6667371 (2003-12-01), Ng et al.
patent: 6670398 (2003-12-01), Edwards et al.
patent: 6673807 (2004-01-01), Sakai et al.
patent: 6713081 (2004-03-01), Robinson et al.
patent: 6864232 (2005-03-01), Ueno
patent: 6872383 (2005-03-01), Ueno
patent: 2001/0023245 (2001-09-01), Okamoto
patent: 2003/0181692 (2003-09-01), Ni et al.
patent: 2004/0106546 (2004-06-01), Napoli
patent: 2004/0162315 (2004-08-01), Hellberg et al.
patent: 2005/0063996 (2005-03-01), Peyman
patent: 2005/0063997 (2005-03-01), Peyman
patent: 2005/0256065 (2005-11-01), Harris et al.
patent: 17386/88 (1988-06-01), None
patent: 20350/92 (1992-07-01), None
patent: 1333018 (2002-01-01), None
patent: 1340358 (2002-03-01), None
patent: 1456350 (2003-11-01), None
patent: 19810655 (1999-09-01), None
patent: 1074255 (2001-02-01), None
patent: 1142566 (2001-10-01), None
patent: 0 532 862 (2003-03-01), None
patent: 07010752 (1995-01-01), None
patent: 1997030966 (1997-02-01), None
patent: 09315954 (1997-12-01), None
patent: 10-218787 (1998-08-01), None
patent: 2001-064198 (2001-03-01), None
patent: WO 89/01772 (1989-03-01), None
patent: WO 99/22722 (1999-05-01), None
patent: WO 99/34830 (1999-07-01), None
patent: WO 99/42104 (1999-08-01), None
patent: WO 00/66122 (2000-11-01), None
patent: WO 02/24234 (2002-03-01), None
patent: WO 02085928 (2002-10-01), None
patent: WO 03/017990 (2003-03-01), None
patent: 2003047525 (2003-06-01), None
patent: WO 03/051385 (2003-06-01), None
patent: WO 2004/014373 (2004-02-01), None
patent: WO2004/027027 (2004-04-01), None
patent: WO 2004/043480 (2004-05-01), None
patent: WO 2004/096261 (2004-11-01), None
patent: 2005011813 (2005-02-01), None
patent: WO 2005/011813 (2005-02-01), None
patent: WO2005/027906 (2005-03-01), None
patent: 2005030205 (2005-04-01), None
patent: WO 2005/030205 (2005-04-01), None
Ang et al. Dry eye after refractive surgery. Curr Opin Ophthalmol. Aug. 2001;12(4):318-22.
Kaminska et al. Molecular mechanisms of neuroprotective action of immunosuppressants—facts and hypotheses. J Cell Mol Med. Jan.-Mar. 2004;8(1):45-58.
Tonra. Classical and novel directions in neurotrophin transport and research: anterograde transport of brain-derived neurotrophic factor by sensory neurons. Microsc Res Tech. May 15-Jun. 1, 1999, 45(4-5): 225-32.
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=RESTASIS.
LASIK Eye Surgery: What are the risks and how can I find the right doctor for me? Retrieved May 5, 2008 from US Food and Drug Administration web site at http://www.fda.gov/cdrh/lasik/risks.htm.
Dua HS, Azuara-Blanco A. Corneal allograft rejection: Risk factors, diagnosis, prevention, and treatment. Indian J Ophthalmol 1999;47:3-9.
Raivich et al. The making of successful axonal regeneration: Genes, molecules and signal transduction pathways. Brain Res Rev. Feb. 2007;53(2):287-311. Epub Oct. 31, 2006.
Algvere PV, et al,Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD, European J of Ophthalmology (1999), 9(3):217-320.
Anderson, DH, et al.,A role for Local Inflammation in the Formation of Drusen in the Aging Eye, American Journal of Ophthalmology, vol. 134, No. 3, Sep. 2002, pp. 411-431.
Apel, a et al.,A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy, Current Eye Research, vol. 14, No. 8, Aug. 1995, pp. 659-667.
Aramant et al.,Retinal transplantation, Science & Medicines (2000), 7:20-29.
D. Aron-Rosa,Pulsed Nd:YAG lasers in ophthalmology, Nd:YAG Laser Applications, pp. 34-48.
Bakalash,Antigenic Specificity of Immunoprotective Therapeutic Vaccination for Glaucoma, Invest Ophthalmol Vis Sci 2003; 44:3374-3381.
Carmo, et al.,Effect of Cyclosporin A on the blood-retinal barrier permeability in streptotocin-induced diabetes, Mediators of Inflammation (2000), 9(5):243-248.
Chiou,Topical Treatment of Ocular Hypertension, Glaucoma, Ischemic Retinopathy and Age-Related Macular Degeneration with Ophthalmic Formulation of Dopamine Antagonists, U.S. Patent Publication No. US 2003/0069232, published Apr. 10, 2003.
Cicciarell et al,Pharmacokinetics of subconjunctivally administered cyclosporine A. Local delivery prior to chemotherapy for retinoblastoma, IOVS (Mar. 15, 2001), 42(4):S332.
Cooper et al.,Transscleral Delivery, U.S. Patent Application Publication No. US2005/0064010, Published on Mar. 24, 2005, U.S. Appl. No. 10/945,682, filed Sep. 20, 2004.
Das et al.,The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study, Experimental Neurology (1999), 157:58-68.
Del Cerro M et al,Histologic correlation of human neural retinal transplantation, Ophthalmology & Visual Science (2000), 41(10):3142-3148.
Steven H. Dewey, MD,2003 PCO Update: Part 1—How the square-edged IOL prevenst posterior capsular opacification, Cataract & Refractive Surgery Today, Sep. 2003, pp. 20-22.
Donnenfeld, ED, et al.,Cyclosporine provides effective treatment for dry eye, Therapeutic Updates in Ophthalmology, Special Issue, Jul. 1999, pp. 1-3.
Enyedi LB, et al.,Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine(CsA)and dexamethasone(DEX), Investigative Ophthalmology and Visual Science, vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994, abstract.
Enyedi, LB et al.,An intravitreal device providing sustained release of cyclosporine and dexamethasone, Current Eye Research, May 1996, vol. 15, No. 5, pp. 549-557.
Freeman et al.,The Effects of FK506 on Retinal Ganglion Cells after Optic Nerve Crush, Invest Opthalmol Vis Sci, 2000; 41:1111-1115.
Garweg, J et al.,Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine, Klinische Monatsblatter for Augenheiljunde, vol. 199, No. 3, Sep. 1991, pp, 199-205.
Gilbard, JP,EW Interview: Electrolyte balance is key to dry-eye product's success, EyeWorld, Feb. 1999, pp. 20ff.
Goodman & Gilman,The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, New York, 1990, pp. 1024-1033.
Grisolano et al.,Retinal Toxicity Study of Intravitreal Cyclosporin, Opthalmic Surgery, Mar. 1986, 17:155-156.
Hageman et al.,Diagnostics and Therapeutics for Macular Degeneration-Related Disorders, U.S. Patent Application Publication N
Allergan, Inc.
Condino Debra D.
Emch Gregory S
German Joel B.
Kemmerer Elizabeth C.
LandOfFree
Enhanced ocular neuroprotection and neurostimulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced ocular neuroprotection and neurostimulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced ocular neuroprotection and neurostimulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251955